An observational study in Obstructive Sleep Apnea and Metabolic Dysfunction-Associated Steatotic Liver Disease, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Assiut University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Sleep Apnea, Obstructive by Assiut University — 7 open to participants now, 7 under way, none of them phase 3. Sleep Apnea, Obstructive · Assiut University.
Among the 13 studies in Sleep Apnea, Obstructive by Assiut University, this one has the largest planned enrollment of the 11 observational ones that give a count, is one of 4 that started in 2026, is one of 11 observational ones, and was the 12th registered.
2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.
Browse Sleep Apnea, Obstructive studies →7 of the 13 studies in Sleep Apnea, Obstructive by Assiut University are open now. Recruiting first, the newest first:
Assiut University
Ages 18+
Assiut University
Ages 18+
Assiut University
Ages 18+
Assiut University
Ages 18–65
Assiut University
Ages 18–60
Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 4 started in 2026.
This study's planned enrollment of 127 is above the median of 105 across 668 observational studies indexed under Sleep Apnea, Obstructive.
Median enrollment 30 across the 2 interventional studies, 80 across the 11 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assiut University is the lead sponsor of 5,094 studies on the registry; 2,187 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
5 of the studies in Sleep Apnea, Obstructive by Assiut University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07716995Assiut UniversityAssociation Between Metabolic Associated Fatty Liver Disease and Obstructive Sleep Apnea | 2027-02-01 |
| NCT07184060Assiut UniversityEchocardiographic Assessment of Pulmonary Hypertension in Obstructive Sleep Apnea | 2027-04-30 |
| NCT07693101Assiut UniversityEmpirical CPAP Therapy for Suspected Obstructive Sleep Apnea in a Resource-Limited Setting | 2027-08 |
| NCT07678918Assiut UniversityCognitive Function and Quality of Life in Obstructive Sleep Apnea | 2027-08 |
| NCT07935057Assiut UniversityDiaphragmatic Ultrasound and Hypoxic Burden in "Osa" | 2027-11-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 13 studies in Sleep Apnea, Obstructive by Assiut University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Association between Metabolic Associated Fatty Liver Disease and Obstructive Sleep Apnea
Obstructive sleep apnea (OSA) is an increasingly common disorder that is characterized by periodic collapse of the upper airway resulting in cycles of hypoxia and reoxygenation known as chronic intermittent hypoxia(CIH). Evidence has shown that OSA can contribute to the development of many metabolic abnormalities (such as obesity, hyperglycemia, dyslipidemia, and the metabolic syndrome).
Metabolic associated fatty liver disease (MAFLD) has become more common in recent years. MAFLD is thought to be the primary cause of chronic liver disorders, and it has grown to be a significant global public health concern. The prevalence of MAFLD has been steadily rising due to changes in lifestyle and dietary patterns, making it the most common chronic liver ailment globally. The global prevalence of MAFLD is 30.1%.
Evidence emerged that linked OSA severity with the development and progression of MAFLD. For example, CIH (a hallmark of OSA) was identified as an independent risk factor in the onset and progression of MAFLD. The essential links between CIH and MAFLD involve insulin resistance, glucose dysregulation, dysfunction of key steps in hepatic lipid metabolism, oxidative stress, and hepatic steatosis and fibrosis, which together indicate that metabolic dysfunction plays a significant role in the pathogenesis of CIH-associated MAFLD
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Correlation Between Apnea-Hypopnea Index and MASLD
To assess the correlation between the Apnea-Hypopnea Index (AHI), measured by overnight polysomnography (events/hour), and hepatic steatosis measured by FibroScan with Controlled Attenuation Parameter (CAP), reported in decibels per meter (dB/m).
Time frame: At baseline
No study locations are listed for this record.
Start is estimated for Dec 2026; primary completion for Feb 2027, 2 months later.
Of 258 non-industry observational studies under Sleep Apnea, Obstructive, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 63. This study's planned 2 months is below that.
Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 14 and three quarters within 63.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: start Aug 2026 → Dec 2026 and primary completion Sep 2026 → Feb 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.